Tag: Parkinson’s
Glitazone Usage Tied to Lower Risk for Parkinson’s Disease
Lower risk of Parkinson's seen only with current use of glitazone
FDA: Brain Stimulation Device Approved for Parkinson’s
For use in Parkinson's disease and essential tremor after medication alone proves inadequate
TBI Linked to Parkinson’s Risk in Patients Aged ≥55 Years
Dose-response associations identified for traumatic brain injury severity and frequency
History of Depression May Raise Parkinson’s Risk
Study finds association, but overall risk is low -- only about 1 percent
Protein Seen in Parkinson’s May Activate Immune System
Candesartan and an experimental drug both reduce the immune response
Lasting Pain Relief With Deep Brain Stimulation in Parkinson’s
Improvement in pain lasts during eight-year follow-up; however, new pain can develop during follow-up
Findings Do Not Support Creatine for Parkinson’s Rx
Research in mice had suggested oral creatine supplementation might help
Biomarkers Show Potential for Parkinson’s Diagnosis
Researchers also hope it will help doctors track treatment
Cost of Meds Contributes to Placebo Effect in Parkinson’s
Parkinson's patients given fake drugs fared better on 'more expensive' medication
